MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Journal of Crohn s and Colitis
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,681 results · 1 filter active ·
Results by year
20072025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,681 works in the cohort · of 4,299,418page 9 of 34

Labels cover 4 of 1,681 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,681 of 1,681 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial
B E Sands, Remo Panaccione, Geert D’Haens, Stefan Schreiber, Aaron DuVall, Jarosław Kierkuś +9 more
2024· article· en· Journal of Crohn s and Colitis· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
6
citations
affunlabeled
ECCO Topical Review on Pouch Disorders
Maia Kayal, Gabriele Bislenghi, Michel Adamina, Zaid Ardalan, Nicolás Avellaneda, Anthony de Buck van Overstraeten +8 more
2025· review· en· Journal of Crohn s and Colitis· Health Professions
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
Stephen B. Hanauer, Remo Panaccione, Silvio Danese, Adam S. Cheifetz, Walter Reinisch, Peter Higgins +7 more
2018· article· en· Journal of Crohn s and Colitis· Pharmacology, Toxicology and Pharmaceutics
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial
Stefan Schreiber, Brian G. Feagan, Laurent Peyrin‐Biroulet, Séverine Vermeire, Margaux Faes, Kristina Harris +4 more
2022· article· en· Journal of Crohn s and Colitis· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
5
citations

How this was built: Screen · Findings · About